Glycaemic control in insulin deficient patients using different insulin delivery and glucose sensoring devices: Cross-sectional real-life study - 16/04/22
, Päivi Hannula a, b, Heini Huhtala c, Saara Metso a, b
Bienvenue sur EM-consulte, la référence des professionnels de santé.
Article gratuit.
Connectez-vous pour en bénéficier!
Highlights |
• | Glucose determination method and treatment modality affect glycaemic control as an independent risk factor in addition to age. |
• | The youngest patients had the most room for improvement in the glycaemic control. |
• | Closed insulin pump systems were more effective than open systems. |
Abstract |
Aims |
To assess glycaemic control in ≥15-year-old patients with type 1 diabetes treated in Tampere University Hospital in a real-life cross-sectional registry study.
Methods |
Glycaemic control was assessed with HbA1c, time in range (TIR) and the incidence of acute complications. The effect of age, BMI, gender, duration of diabetes, daily insulin dose, and device group on the glycaemic control was studied.
Results |
The study included 1,132 patients. Eighty-four percent of the patients had TIR≤70%. Two percent of patients had an episode of diabetic ketoacidosis and 0,2% had severe hypoglycemia within the last 12 months. Intermittently scanned CGM (IsCGM) with MDI was used in 59%, continuous subcutaneous insulin infusion (CSII) with glucose sensor in 15%, and sensor-augmented/hybrid closed-loop pump (SAP/HCL) in 9% of the patients. In the logistic regression analysis, TIR≤70% was associated with young age group (OR 2.70; 95% CI 1.43–5.09) and daily insulin dose per weight (OR 6.66; 95% CI 3.53–12.57). CSII with glucose sensor and IsCGM with MDI were associated with poor glycaemic control compared to SAP/HCL.
Conclusion |
There is room for improvement in the glycaemic control in our area although serious acute complications are rare. Closed insulin pump system was more effective than open system.
Le texte complet de cet article est disponible en PDF.Keywords : Type 1 diabetes, Glycemic control, Time in range, Blood glucose monitoring, Insulin pump, Diabetic ketoacidosis
Plan
Vol 7
Article 100072- juillet 2022 Retour au numéro
Article précédent
- Next-generation sequencing technologies in diabetes research
- Mohd Fareed, Waseem Chauhan, Rafat Fatma, Inshah Din, Mohammad Afzal, Zabeer Ahmed
- Is REmogliflozin an effective Drug in MANaging Type-2 diabetes mellitus: A comparative study – (REDMAN)
- Prabhat Agrawal, Nikhil Pursnani, Ashish Gautam, Ruchika Garg
Bienvenue sur EM-consulte, la référence des professionnels de santé.